Micromarkers: miRNAs in cancer diagnosis and prognosis

References

• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell116(2), 281–297 (2004).
   PubMed Web of Science ®Google Scholar
• Winter J, Jung S, Keller S et al. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat. Cell. Biol.11(3), 228–234 (2009).
   PubMed Web of Science ®Google Scholar
• Lim LP, Lau NC, Garrett-Engele P et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature433(7027), 769–773 (2005).
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell136(2), 215–233 (2009).
   PubMed Web of Science ®Google Scholar
• Brodersen P, Voinnet O. Revisiting the principles of microRNA target recognition and mode of action. Nat. Rev. Mol. Cell. Biol.10(2), 141–148 (2009).
   PubMed Web of Science ®Google Scholar
• Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science318(5858), 1931–1934 (2007).
   PubMed Web of Science ®Google Scholar
• Papadopoulos GL, Reczko M, Simossis VA et al. The database of experimentally supported targets: a functional update of TarBase. Nucleic Acids Res.37(Database issue), D155–D158 (2009).
   PubMed Web of Science ®Google Scholar
• Sethupathy P, Corda B, Hatzigeorgiou AG. TarBase: A comprehensive database of experimentally supported animal microRNA targets. RNA12(2), 192–197 (2006).
   PubMed Web of Science ®Google Scholar
• John B, Enright AJ, Aravin A et al. Human MicroRNA targets. PLoS Biol.2(11), e363 (2004).
   PubMed Web of Science ®Google Scholar
• Krek A, Grun D, Poy MN et al. Combinatorial microRNA target predictions. Nat. Genet.37(5), 495–500 (2005).
   PubMed Web of Science ®Google Scholar
• Lewis BP, Shih IH, Jones-Rhoades MW et al. Prediction of mammalian microRNA targets. Cell115(7), 787–798 (2003).
   PubMed Web of Science ®Google Scholar
• Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell120(1), 15–20 (2005).
   PubMed Web of Science ®Google Scholar
• Maragkakis M, Alexiou P, Papadopoulos GL et al. Accurate microRNA target prediction correlates with protein repression levels. BMC Bioinformatics10(295 (2009).
   PubMedGoogle Scholar
• Maragkakis M, Reczko M, Simossis VA et al. DIANA-microT web server: elucidating microRNA functions through target prediction. Nucleic Acids Res.37(Web Server issue), W273–W276 (2009).
   PubMed Web of Science ®Google Scholar
• Kertesz M, Iovino N, Unnerstall U et al. The role of site accessibility in microRNA target recognition. Nat. Genet.39(10), 1278–1284 (2007).
   PubMed Web of Science ®Google Scholar
• Alexiou P, Maragkakis M, Papadopoulos GL et al. Lost in translation: an assessment and perspective for computational microRNA target identification. Bioinformatics25(23), 3049–3055 (2009).
   PubMed Web of Science ®Google Scholar
• Lagos-Quintana M, Rauhut R, Lendeckel W et al. Identification of novel genes coding for small expressed RNAs. Science294(5543), 853–858 (2001).
   PubMed Web of Science ®Google Scholar
• Lagos-Quintana M, Rauhut R, Meyer J et al. New microRNAs from mouse and human. RNA9(2), 175–179 (2003).
   PubMed Web of Science ®Google Scholar
• Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA99(24), 15524–15529 (2002).
   PubMed Web of Science ®Google Scholar
• Calin GA, Liu CG, Sevignani C et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl Acad. Sci. USA101(32), 11755–11760 (2004).
   PubMed Web of Science ®Google Scholar
• Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat. Rev. Cancer6(11), 857–866 (2006).
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. Nat. Rev. Cancer6(4), 259–269 (2006).
   PubMed Web of Science ®Google Scholar
• Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet.10(10), 704–714 (2009).
   PubMed Web of Science ®Google Scholar
• Li J, Smyth P, Flavin R et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol.7, 36 (2007).
   PubMed Web of Science ®Google Scholar
• Doleshal M, Magotra AA, Choudhury B et al. Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues. J. Mol. Diagn.10(3), 203–211 (2008).
   PubMed Web of Science ®Google Scholar
• Xi Y, Nakajima G, Gavin E et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA13(10), 1668–1674 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenfeld N, Aharonov R, Meiri E et al. MicroRNAs accurately identify cancer tissue origin. Nat. Biotechnol.26(4), 462–469 (2008).
   PubMed Web of Science ®Google Scholar
• Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur. J. Cancer43(14), 2026–2036 (2007).
   PubMed Web of Science ®Google Scholar
• Baek D, Villen J, Shin C et al. The impact of microRNAs on protein output. Nature455(7209), 64–71 (2008).
   PubMed Web of Science ®Google Scholar
• Lanza G, Ferracin M, Gafa R et al. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol. Cancer6, 54 (2007).
   PubMed Web of Science ®Google Scholar
• Lionetti M, Biasiolo M, Agnelli L et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood114(25), 20–26 (2009).
   PubMed Web of Science ®Google Scholar
• Fulci V, Colombo T, Chiaretti S et al. Characterization of B- and T-lineage acute lymphoblastic leukemia by integrated analysis of MicroRNA and mRNA expression profiles. Genes Chromosomes Cancer48(12), 1069–1082 (2009).
   PubMed Web of Science ®Google Scholar
• Calin GA, Ferracin M, Cimmino A et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med.353(17), 1793–1801 (2005).
   PubMed Web of Science ®Google Scholar
• Bloomston M, Frankel WL, Petrocca F et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA297(17), 1901–1908 (2007).
   PubMed Web of Science ®Google Scholar
• Budhu A, Jia HL, Forgues M et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology47(3), 897–907 (2008).
   PubMed Web of Science ®Google Scholar
• Fornari F, Gramantieri L, Giovannini C et al. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res.69(14), 5761–5767 (2009).
   PubMed Web of Science ®Google Scholar
• Gramantieri L, Fornari F, Ferracin M et al. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin. Cancer Res..15(16), 5073–5081 (2009).
   PubMed Web of Science ®Google Scholar
• Schetter AJ, Nguyen GH, Bowman ED et al. Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin. Cancer Res..15(18), 5878–5887 (2009).
   PubMed Web of Science ®Google Scholar
• Diaz R, Silva J, Garcia JM et al. Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer47(9), 794–802 (2008).
   PubMed Web of Science ®Google Scholar
• Yanaihara N, Caplen N, Bowman E et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell9(3), 189–198 (2006).
   PubMed Web of Science ®Google Scholar
• Takamizawa J, Konishi H, Yanagisawa K et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res.64(11), 3753–3756 (2004).
   PubMed Web of Science ®Google Scholar
• Yu SL, Chen HY, Chang GC et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell13(1), 48–57 (2008).
   PubMed Web of Science ®Google Scholar
• Gallardo E, Navarro A, Vinolas N et al.miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis30(11), 1903–1909 (2009).
   PubMed Web of Science ®Google Scholar
• Corney DC, Flesken-Nikitin A, Godwin AK et al. MicroRNA-34b and microRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res.67(18), 8433–8438 (2007).
   PubMed Web of Science ®Google Scholar
• He L, He X, Lowe SW et al. microRNAs join the p53 network – another piece in the tumour-suppression puzzle. Nat. Rev. Cancer7(11), 819–822 (2007).
   PubMed Web of Science ®Google Scholar
• Mraz M, Malinova K, Kotaskova J et al. miR-34a, miR-29c and miR-17–5p are downregulated in CLL patients with TP53 abnormalities. Leukemia23(6), 1159–1163 (2009).
   PubMed Web of Science ®Google Scholar
• Zenz T, Mohr J, Eldering E et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood113(16), 3801–3808 (2009).
   PubMed Web of Science ®Google Scholar
• Mathe EA, Nguyen GH, Bowman ED et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin. Cancer Res.15(19), 6192–6200 (2009).
   PubMed Web of Science ®Google Scholar
• Li J, Huang H, Sun L et al. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin. Cancer Res.15(12), 3998–4008 (2009).
   PubMed Web of Science ®Google Scholar
• Satzger I, Mattern A, Kuettler U et al. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int. J. Cancer DOI: 10.1002/ijc.24960 (2009) (Epub ahead of print).
   Google Scholar
• Lawrie CH, Gal S, Dunlop HM et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol.141(5), 672–675 (2008).
   PubMed Web of Science ®Google Scholar
• Salter KH, Acharya CR, Walters KS et al. An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS ONE3(4), e1908 (2008).
   PubMed Web of Science ®Google Scholar
• Blower PE, Chung JH, Verducci JS et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol. Cancer Ther.7(1), 1–9 (2008).
   PubMed Web of Science ®Google Scholar
• Meng F, Henson R, Lang M et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology130(7), 2113–2129 (2006).
   PubMed Web of Science ®Google Scholar
• Yang H, Kong W, He L et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res.68(2), 425–433 (2008).
   PubMed Web of Science ®Google Scholar
• Svoboda M, Izakovicova Holla L, Sefr R et al. Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer. Int. J. Oncol.33(3), 541–547 (2008).
   PubMed Web of Science ®Google Scholar
• Ji J, Shi J, Budhu A et al. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med.361(15), 1437–1447 (2009).
   PubMed Web of Science ®Google Scholar
• Mishra PJ, Humeniuk R, Longo-Sorbello GS et al. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc. Natl Acad. Sci. USA104(33), 13513–13518 (2007).
   PubMed Web of Science ®Google Scholar
• Mishra PJ, Banerjee D, Bertino JR. MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: introducing microRNA pharmacogenomics. Cell Cycle7(7), 853–858 (2008).
   PubMed Web of Science ®Google Scholar
• Mishra PJ, Bertino JR. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics10(3), 399–416 (2009).
   PubMed Web of Science ®Google Scholar
• Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA105(30), 10513–10518 (2008).
   PubMed Web of Science ®Google Scholar
• Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res.18(10), 997–1006 (2008).
   PubMed Web of Science ®Google Scholar
• Ng EK, Chong WW, Jin H et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut58(10), 1375–1381 (2009).
   PubMed Web of Science ®Google Scholar
• Resnick KE, Alder H, Hagan JP et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol.112(1), 55–59 (2009).
   PubMed Web of Science ®Google Scholar
• Tanaka M, Oikawa K, Takanashi M et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS ONE4(5), e5532 (2009).
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Kosaka N, Tanaka M et al. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers14(7) 529–538 (2009).
   PubMed Web of Science ®Google Scholar
• Saunders MA, Liang H, Li WH. Human polymorphism at microRNAs and microRNA target sites. Proc. Natl Acad. Sci. USA104(9), 3300–3305 (2007).
   PubMed Web of Science ®Google Scholar
• Raveche ES, Salerno E, Scaglione BJ et al. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood109(12), 5079–5086 (2007).
   PubMed Web of Science ®Google Scholar
• Duan R, Pak C, Jin P. Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum. Mol. Genet.16(9), 1124–1131 (2007).
   PubMed Web of Science ®Google Scholar
• Iorio MV, Ferracin M, Liu CG et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res.65(16), 7065–7070 (2005).
   PubMed Web of Science ®Google Scholar
• Jazdzewski K, Murray EL, Franssila K et al. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc. Natl Acad. Sci. USA105(20), 7269–7274 (2008).
   PubMed Web of Science ®Google Scholar
• Shen J, Ambrosone CB, DiCioccio RA et al. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis29(10), 1963–1966 (2008).
   PubMed Web of Science ®Google Scholar
• Xu T, Zhu Y, Wei QK et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis29(11), 2126–2131 (2008).
   PubMed Web of Science ®Google Scholar
• Jazdzewski K, Liyanarachchi S, Swierniak M et al. Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc. Natl Acad. Sci. USA106(5), 1502–1505 (2009).
   PubMed Web of Science ®Google Scholar
• Hu Z, Liang J, Wang Z et al. Common genetic variants in pre-microRNAs were associated with increased risk of breast cancer in Chinese women. Hum. Mutat.30(1), 79–84 (2009).
   PubMed Web of Science ®Google Scholar
• Hoffman AE, Zheng T, Yi C et al. microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Res.69(14), 5970–5977 (2009).
   PubMed Web of Science ®Google Scholar
• Hu Z, Chen J, Tian T et al. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J. Clin. Invest.118(7), 2600–2608 (2008).
   PubMed Web of Science ®Google Scholar
• Ye Y, Wang KK, Gu J et al. Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev. Res. (Phila. PA)1(6), 460–469 (2008).
   PubMed Web of Science ®Google Scholar
• Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA103(7), 2257–2261 (2006).
   PubMed Web of Science ®Google Scholar
• Roldo C, Missiaglia E, Hagan JP et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol.24(29), 4677–4684 (2006).
   PubMed Web of Science ®Google Scholar
• Gottardo F, Liu CG, Ferracin M et al. Micro-RNA profiling in kidney and bladder cancers. Urol. Oncol.25(5), 387–392 (2007).
   PubMed Web of Science ®Google Scholar
• Wong TS, Liu XB, Chung-Wai Ho A et al. Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling. Int. J. Cancer123(2), 251–257 (2008).
   PubMed Web of Science ®Google Scholar
• He H, Jazdzewski K, Li W et al. The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl Acad. Sci. USA102(52), 19075–19080 (2005).
   PubMed Web of Science ®Google Scholar
• Eis PS, Tam W, Sun L et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc. Natl Acad. Sci. USA102(10), 3627–3632 (2005).
   PubMed Web of Science ®Google Scholar
• Costinean S, Zanesi N, Pekarsky Y et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc. Natl Acad. Sci. USA103(18), 7024–7029 (2006).
   PubMed Web of Science ®Google Scholar
• Mendell JT. miRiad roles for the miR-17–92 cluster in development and disease. Cell133(2), 217–222 (2008).
   PubMed Web of Science ®Google Scholar
• Xiao C, Srinivasan L, Calado DP et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17–92 expression in lymphocytes. Nat. Immunol.9(4), 405–414 (2008).
   PubMed Web of Science ®Google Scholar
• Ventura A, Young AG, Winslow MM et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell132(5), 875–886 (2008).
   PubMed Web of Science ®Google Scholar
• Wong TS, Liu XB, Wong BY et al. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin. Cancer Res.14(9), 2588–2592 (2008).
   PubMed Web of Science ®Google Scholar
• Ji J, Yamashita T, Budhu A et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology50(2), 472–480 (2009).
   PubMed Web of Science ®Google Scholar
• Murakami Y, Yasuda T, Saigo K et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene25(17), 2537–2545 (2006).
   PubMed Web of Science ®Google Scholar
• Nam EJ, Yoon H, Kim SW et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin. Cancer Res.14(9), 2690–2695 (2008).
   PubMed Web of Science ®Google Scholar
• Meng F, Henson R, Wehbe-Janek H et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology133(2), 647–658 (2007).
   PubMed Web of Science ®Google Scholar
• Jiang J, Gusev Y, Aderca I et al. Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin. Cancer Res.14(2), 419–427 (2008).
   PubMed Web of Science ®Google Scholar
• Ciafre SA, Galardi S, Mangiola A et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys. Res. Commun.334(4), 1351–1358 (2005).
   PubMed Web of Science ®Google Scholar
• Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res.65(14), 6029–6033 (2005).
   PubMed Web of Science ®Google Scholar
• Garzon R, Volinia S, Liu CG et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood111(6), 3183–3189 (2008).
   PubMed Web of Science ®Google Scholar
• Fulci V, Chiaretti S, Goldoni M et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood109(11), 4944–4951 (2007).
   PubMed Web of Science ®Google Scholar
• Porkka KP, Pfeiffer MJ, Waltering KK et al. MicroRNA expression profiling in prostate cancer. Cancer Res.67(13), 6130–6135 (2007).
   PubMed Web of Science ®Google Scholar
• Gramantieri L, Ferracin M, Fornari F et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res.67(13), 6092–6099 (2007).
   PubMed Web of Science ®Google Scholar
• Pallante P, Visone R, Ferracin M et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr. Relat. Cancer13(2), 497–508 (2006).
   PubMed Web of Science ®Google Scholar
• Felicetti F, Errico MC, Bottero L et al. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res.68(8), 2745–2754 (2008).
   PubMed Web of Science ®Google Scholar
• Galardi S, Mercatelli N, Giorda E et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J. Biol. Chem.282(32), 23716–23724 (2007).
   PubMed Web of Science ®Google Scholar
• Veerla S, Lindgren D, Kvist A et al. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int. J. Cancer124(9), 2236–2242 (2009).
   PubMed Web of Science ®Google Scholar
• Lee EJ, Gusev Y, Jiang J et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer120(5), 1046–1054 (2007).
   PubMed Web of Science ®Google Scholar
• Huang Q, Gumireddy K, Schrier M et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat. Cell. Biol.10(2), 202–210 (2008).
   PubMed Web of Science ®Google Scholar
• Voorhoeve PM, le Sage C, Schrier M et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell124(6), 1169–1181 (2006).
   PubMed Web of Science ®Google Scholar
• Sampson VB, Rong NH, Han J et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res.67(20), 9762–9770 (2007).
   PubMed Web of Science ®Google Scholar
• Inamura K, Togashi Y, Nomura K et al. let-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a non-invasive carcinoma, and is not correlated with prognosis. Lung Cancer58(3), 392–396 (2007).
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Trang P, Wiggins JF et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle7(6), 759–764 (2008).
   PubMed Web of Science ®Google Scholar
• Yu F, Yao H, Zhu P et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell131(6), 1109–1123 (2007).
   PubMed Web of Science ®Google Scholar
• Iorio MV, Visone R, Di Leva G et al. MicroRNA signatures in human ovarian cancer. Cancer Res.67(18), 8699–8707 (2007).
   PubMed Web of Science ®Google Scholar
• Friedman JM, Liang G, Liu CC et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res.69(6), 2623–2629 (2009).
   PubMed Web of Science ®Google Scholar
• Su H, Yang JR, Xu T et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res.69(3), 1135–1142 (2009).
   PubMed Web of Science ®Google Scholar
• Strillacci A, Griffoni C, Sansone P et al. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp. Cell Res.315(8), 1439–1447 (2009).
   PubMed Web of Science ®Google Scholar
• Varambally S, Cao Q, Mani RS et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science322(5908), 1695–1699 (2008).
   PubMed Web of Science ®Google Scholar
• Li W, Xie L, He X et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int. J. Cancer123(7), 1616–1622 (2008).
   PubMed Web of Science ®Google Scholar
• Ferretti E, De Smaele E, Po A et al. MicroRNA profiling in human medulloblastoma. Int. J. Cancer124(3), 568–577 (2009).
   PubMed Web of Science ®Google Scholar
• Liu X, Jiang L, Wang A et al. MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines. Cancer Lett.286(2), 217–222 (2009).
   PubMed Web of Science ®Google Scholar
• Michael MZ, SM OC, van Holst Pellekaan NG et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol. Cancer Res.1(12), 882–891 (2003).
   PubMed Web of Science ®Google Scholar
• Akao Y, Nakagawa Y, Kitade Y et al. Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci.98(12), 1914–1920 (2007).
   PubMed Web of Science ®Google Scholar
• Calin GA, Sevignani C, Dumitru CD et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl Acad. Sci. USA101(9), 2999–3004 (2004).
   PubMed Web of Science ®Google Scholar
• Cimmino A, Calin GA, Fabbri M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci. USA102(39), 13944–13949 (2005).
   PubMed Web of Science ®Google Scholar
• Bottoni A, Piccin D, Tagliati F et al. miR-15a and miR-16–1 down-regulation in pituitary adenomas. J. Cell. Physiol.204(1), 280–285 (2005).
   PubMed Web of Science ®Google Scholar
• Bonci D, Coppola V, Musumeci M et al. The miR-15a–miR-16–1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med.14(11), 1271–1277 (2008).
   PubMed Web of Science ®Google Scholar
• Bandi N, Zbinden S, Gugger M et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res.69(13), 5553–5559 (2009).
   PubMed Web of Science ®Google Scholar
• Lerner M, Harada M, Loven J et al. DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16–1. Exp. Cell Res.315(17), 2941–2952 (2009).
   PubMed Web of Science ®Google Scholar
• Ichimi T, Enokida H, Okuno Y et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int. J. Cancer125(2), 345–352 (2009).
   PubMed Web of Science ®Google Scholar
• Kalscheuer S, Zhang X, Zeng Y et al. Differential expression of microRNAs in early-stage neoplastic transformation in the lungs of F344 rats chronically treated with the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis29(12), 2394–2399 (2008).
   PubMed Web of Science ®Google Scholar
• Fabbri M, Garzon R, Cimmino A et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl Acad. Sci. USA104(40), 15805–15810 (2007).
   PubMed Web of Science ®Google Scholar
• Pekarsky Y, Santanam U, Cimmino A et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res.66(24), 11590–11593 (2006).
   PubMed Web of Science ®Google Scholar
• Sengupta S, den Boon JA, Chen IH et al. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc. Natl Acad. Sci. USA105(15), 5874–5878 (2008).
   PubMed Web of Science ®Google Scholar
• Mott JL, Kobayashi S, Bronk SF et al. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene26(42), 6133–6140 (2007).
   PubMed Web of Science ®Google Scholar
• Gebeshuber CA, Zatloukal K, Martinez J. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep.10(4), 400–405 (2009).
   PubMed Web of Science ®Google Scholar
• Garzon R, Garofalo M, Martelli MP et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc. Natl Acad. Sci. USA105(10), 3945–3950 (2008).
   PubMed Web of Science ®Google Scholar
• Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene26(34), 5017–5022 (2007).
   PubMed Web of Science ®Google Scholar
• Rokhlin OW, Scheinker VS, Taghiyev AF et al. MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol. Ther.7(8), 1288–1296 (2008).
   PubMed Web of Science ®Google Scholar
• Toyota M, Suzuki H, Sasaki Y et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res.68(11), 4123–4132 (2008).
   PubMed Web of Science ®Google Scholar
• Lodygin D, Tarasov V, Epanchintsev A et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle7(16), 2591–2600 (2008).
   PubMed Web of Science ®Google Scholar
• Li N, Fu H, Tie Y et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett275(1), 44–53 (2009).
   PubMed Web of Science ®Google Scholar
• Chan SH, Wu CW, Li AF et al. miR-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res.28(2A), 907–911 (2008).
   PubMed Web of Science ®Google Scholar
• Yan LX, Huang XF, Shao Q et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA14(11), 2348–2360 (2008).
   PubMed Web of Science ®Google Scholar
• Schetter AJ, Leung SY, Sohn JJ et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA299(4), 425–436 (2008).
   PubMed Web of Science ®Google Scholar
• Markou A, Tsaroucha EG, Kaklamanis L et al. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin. Chem.54(10), 1696–1704 (2008).
   PubMed Web of Science ®Google Scholar
• Lawrie CH, Soneji S, Marafioti T et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int. J. Cancer121(5), 1156–1161 (2007).
   PubMed Web of Science ®Google Scholar
• Li W, Duan R, Kooy F et al. Germline mutation of microRNA-125a is associated with breast cancer. J. Med. Genet.46(5), 358–360 (2009).
   PubMed Web of Science ®Google Scholar